News

1/30/12 PredictAD final review - excellent progress Read more » 12/15/11 Press release: From heterogeneous patient measurements towards earlier diagnosis in Alzheimer's disease Read more » 12/15/11 Press release: Biochemical signature predicts progression to Alzheimer's disease Read more » 12/13/11 Journal paper in Translational Psychiatry Read more » 8/22/11 PredictAD presented at the VHP NoE Newsletter Read more »

Contact Information

Scientific Coordinator
Jyrki Lötjönen
VTT Technical Research Centre of Finland
P.O. Box 1300
33101 Tampere
+358 20 722 3378
jyrki.lotjonen@vtt.fi

PredictAD

According to the latest estimates, the global prevalence of Alzheimer's disease will quadruple to 106 million by 2050. To date there is no single test or biomarker that can predict whether a particular person will develop the affliction. Thus, there is a critical need for effective diagnostic tools to help in the early diagnosis of this debilitating disease.

PredictAD is an EU funded research project aiming at developing a standardised and objective solution that would enable an earlier diagnosis of Alzheimer’s disease, improved monitoring of treatment efficacy and enhanced cost-effectiveness of diagnostic protocols. The development of novel therapeutics relying on novel biomarkers and diagnostics offers hope to individuals and to society. With a consortium of top-level European research and industrial partners, PredictAD takes the opportunity to warrant that hope as well as strengthen the EU’s leadership on the market in this field.

PredictAD consortium members are VTT Technical Research Centre of Finland, GE Healthcare (UK), Nexstim Ltd. (Finland), University of Kuopio (Finland), Imperial College of London (UK), Karolinska Institutet (Sweden), University of Milan (Italy) and Copenhagen University Hospital, Rigshospitalet (Denmark). This project is partially funded under the 7th Framework Programme by the European Commission.
 
e_health.jpg
 
7th_framework.jpg eu_flag.jpg